Loading...
Post-hoc analyses can produce hypotheses but should be interpreted with care. A post-hoc analysis of the MERLIN-Timi 36 trial suggested that patients with acute coronary syndromes and a history of angina who were treated with percutaneous coronary intervention (PCI) did better with ranolazine than placebo. In the current industry-funded trial, investigators tested a variation of this hypothesis by determining whether ranolazine improves outcomes in patients with incomplete revascularization after PCI.
In the multicenter, double-blind, event-driven-trial, 2651 patients were randomized to ranolazine or placebo and followed for a median of 643 days. The groups did not differ significantly on the primary endpoint of time to first occurrence of i…